Plain-English translation of NCT07216495 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This pilot study is testing whether a supervised exercise program is safe and feasible for people with early-stage triple-negative breast cancer who are undergoing chemotherapy combined with pembrolizumab, an immune checkpoint inhibitor. The researchers want to see if exercise during this type of treatment is possible, and whether it might help strengthen the body's immune cells in fighting cancer.
Triple-negative breast cancer is an aggressive form of breast cancer that doesn't respond to common hormone treatments. While immunotherapy is showing promise for this type of cancer, researchers don't yet know whether adding exercise during treatment could be both safe and beneficial. This study aims to fill that gap.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will participate in 4 supervised exercise sessions conducted at the clinic. These sessions involve supervised aerobic exercise on a treadmill and other cardiorespiratory training, designed to be safe while you're receiving your cancer treatment. You'll also have blood samples taken to measure immune cells, and your doctors will monitor your safety throughout.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~33 participants
Started
February 2026
Primary completion
October 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Salma Foster
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.